Adult Neurogenic Lower Urinary Tract Dysfunction and Intermittent Catheterisation in a Community Setting: Risk Factors Model for Urinary Tract Infections

Michael Kennelly, Nikesh Thiruchelvam, Márcio Augusto Averbeck, Charalampos Konstatinidis, Emmanuel Chartier-Kastler, Pernille Trøjgaard, Rikke Vaabengaard, Andrei Krassioukov, and Birte Petersen Jakobsen

1Department of Urology, Carolinas Medical Center, Charlotte, NC, USA
2Department of Urology, Addenbrooke’s Hospital, Cambridge, UK
3Moinhos de Vento Hospital, Porto Alegre, Brazil
4Urology & Neuro-urology Unit, National Rehabilitation Center, Athens, Greece
5Urology Clinic, Hôpital Raymond Poincaré, Paris, France
6Coloplast A/S, Humlebaek, Denmark
7Division of Physical Medicine and Rehabilitation, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
8G.F. Strong Rehabilitation Centre, Vancouver, British Columbia, Canada
9Independent Medical Consultant, MD, MedDevHealth, Copenhagen, Denmark

Correspondence should be addressed to Michael Kennelly; michael.kennelly@atriumhealth.org

Received 1 February 2019; Accepted 5 March 2019; Published 2 April 2019

A risk factor model for urinary tract infections in patients with adult neurogenic lower urinary tract dysfunction performing clean intermittent catheterisation was developed; it consists of four domains, namely, (1) general (systemic) conditions in the patient, (2) individual urinary tract conditions in the patient, (3) routine aspects related to the patient, and (4) factors related to intermittent catheters per se. The conceptual model primarily concerns patients with spinal cord injury, spina bifida, multiple sclerosis, or cauda equina where intermittent catheterisation is a normal part of the bladder management. On basis of several literature searches and author consensus in case of lacking evidence, the model intends to provide an overview of the risk factors involved in urinary tract infections, with specific emphasis to describe those that in daily practice can be handled and modified by the clinician and so come to the benefit of the individual catheter user in terms of fewer urinary tract infections.

1. Introduction

Adult neurogenic lower urinary tract dysfunction (ANLUTD) refers to “abnormal or difficult function of the bladder, urethra (and/or prostate in men) in mature individuals in the context of clinically confirmed relevant neurologic disorder” [1] (Appendix).

For community, residing ANLUTD subjects, clean intermittent catheterisation (CIC) is the gold standard for bladder emptying, as CIC is the safest method (voluntary, complete, low pressure emptying procedure) in terms of having the lowest potential for urological complications [2]. Indwelling transurethral catheterisation and, to a lesser extent, suprapubic cystostomy should be avoided due to high risk of UTIs and for significant long-term complications [2–4].

CIC is carried out between 16 and 56% of a spinal cord injury (SCI) population, depending on age and severity [5, 6]. In multiple sclerosis (MS) of longer duration, 68%–75% have urinary dysfunction [7, 8]; continuous use of CIC is dependent on the individual’s perception of improvement in
symptoms versus the burden of use and the appearance of a urinary tract infection (UTI) may also negatively influence the use of CIC [9]. In (adult) spina bifida (SB) patients CIC is a cornerstone in bladder treatment [10].

From daily clinical experience, clinical studies, and surveys, it is evident that UTIs are the commonest complication to intermittent catheterisation (IC) and constitutes a major reason for concern in patients and their clinicians and caregivers [11]. The reported UTI incidence rates vary; during the rehabilitation phase of a SCI patient, UTI incidence rates were between 2 and 10 per year [12–19], whereas the UTI rates in the community-based population (>12 months after injury) ranged from 0.8–3.5 per year [20–27]. The present review focusses on community related data.

Several models have been used to describe risk factors for UTI in ANLUTD; Shekelle et al. [28] looked at three domains, the person and their functional level, balanced storage phase, and method of bladder drainage. Bladder emptying methods and residual urine were determined as clear risk factors, whereas reliable evidence was insufficient or missing for other factors. The model presented by Vasudeva and Madersbacher [29] identified intrinsic defence mechanisms, impaired washout, and catheterisation as culprits and concluded that further research is needed to understand the complex interplay between these mechanisms.

In a community-based setting of the ANLUTD population, the authors developed a simple, holistic clinical model (Figure 1) that encompasses four main areas of risk factors related to the neurogenic bladder patients performing IC, general (systemic) conditions, local urinary tract conditions, compliance, and intermittent catheters per se. The model should provide a useful tool to identify risk factors in the individual IC user.

2. Methods

At an initial workshop, upon a discussion of common risk factors for UTI in the IC users, the five experts, representing neurourology, rehabilitation medicine, and urology, expressed a need for a paper describing risk factors for UTI in the ANLUTD population; the model should aim, in a holistic and simple way, to visualise and describe the most in the ANLUTD population; the model should aim, in a holistic and simple way, to visualise and describe the most risk factors involved, with specific emphasis to describe those that in daily practice can be handled and modified by the clinician and so come to the benefit of the individual IC user.

Based on this workshop, two basic searches were performed; one search was performed in PubMed, Embase, and Cinahl using the same terms as in the original 1999 Shekelle et al.’s [28] review. Search: urinary tract, urinary tract infection, bacteriuria, paraplegia, quadriplegia, spinal cord injury, multiple sclerosis, neurogenic bladder, neuropathic bladder. Filters: Comparative Study, Controlled Clinical Trial, Meta-Analysis, Multicenter Study, Systematic Reviews, from 1999/08/01 to 2018/08/01, Humans, English, French, German, Adult: 19+ years. This retrieved 166, 37, and 3 citations in PubMed, Embase, and Cinahl, respectively. The citations in Cinahl and Embase were all included in the PubMed search. Nine relevant publications were identified [14, 17, 18, 20, 24, 30–33].

A further PubMed search was based on a modified Vasudeva search strategy: urinary tract infection, neurogenic bladder, spinal cord injury, spina bifida, multiple sclerosis, cauda equina, bacterial flora, postvoid residual urine, reflux, intermittent catheterisation. Filters: from 1999/08/01 to 2018/08/01, Humans, English, French, German, Adult: 19+ years. This retrieved 8 citations, of which none described risk factors for UTIs. Additional literature searches for each specific risk factor (risk factor and UTI) were performed if deemed necessary.

All potential risk factors detected were presented at a third workshop. Using a modified Delphi approach, each risk factor was evaluated and discussed by the experts and, if found relevant for the model, classified to one of the four domains described above; in case of lacking or inconclusive evidence, the authors concluded by consensus. During this process, the model was finalised. The model intends to provide an overview of the risk factors involved, with specific emphasis to describe those that in daily practice can be handled and modified by the clinician and so come to the benefit of the individual IC user.

3. UTI: Definitions, Diagnoses, and Perceptions

3.1. UTI Definitions and Diagnoses. Uncomplicated UTI is a bacterial presence within the bladder and associated structures in patients with no structural abnormality and no comorbidities, whereas every UTI in patients with ANLUTD per definition are complicated. A key factor complicating the study of UTIs is the lack of consensus regarding its definition [33–35]. Different definitions of UTI for patients relying on IC not only consider laboratory parameters, but also signs and symptoms (Table 1). Among patients with neurourological diseases some present with impaired sensations in the lower urinary tract, like SCI subjects. They may find it difficult to report UTI-related symptoms accurately [36], which imposes a limitation to differentiate asymptomatic bacteriuria (AB) and UTI in the clinical practice. AB is a frequent finding in neurourological patients who perform IC, and it is a constant challenge to distinguish harmless colonization from pathogenic infection. According to international guidelines, prophylactic antibiotics should not be routinely prescribed to neurourological patients with AB, as this treatment might result in significantly more resistant bacterial strains without improving patient outcome.
Intermittent catheterisation
- Bacteria inserted by product and no urethral rinsing
- Urethral and bladder trauma from product
- Post void residual urine due to product design

High intravesical pressure/impaired bladder compliance

Local urinary tract conditions
- Bacterial virulence
- Previous UTI
- Botulinum toxin A injections
- Urodynamic investigations
- Bladder and kidney stones

User compliance/adherence
- Voiding frequency
- Fluid intake
- Non-hygienic procedure
- Insufficient education
- Post void residual urine due to incorrect handling
- Residence country and social support system

General conditions
- Host deficiencies
- Bowel dysfunction
- Diabetes
- Age and gender

Post void residual urine caused by bladder shape

**Figure 1:** The UTI risk factors model with its four domains.

[37, 38]. However, some studies have reported beneficial effect of prophylactic intervention [26, 39].

The controversy regarding UTI definitions was also described in a systematic review trying to more accurately examine the UTI rate following botulinum injections; they found that amongst 50 selected publications, only 27 had defined the UTI with a total of 10 different definitions [43]. Two studies used the National Institute on Disability and Rehabilitation Research [44] UTI definition, whereas no studies used a definition which met the European Association of Urology [4] or Infectious Diseases Society of America [41] criteria.

Biomarkers for UTI have been assessed in a limited number of trials assessed the role of biomarkers, such as interleukins 6 and 8, C-reactive protein, and erythrocyte sedimentation rate, for predicting UTI in humans. Whilst detection of urinary tract infection appears more sensitive with the use of urinary interleukines than that with traditional culture or dipstick techniques, the test is not widely available, is not a simple bedside test, and is more costly than a standard urine dipstick and urine culture testing [35].

Another aspect is the variability regarding definition of recurrent UTIs. Some studies consider 0-1 UTI/year representing no infection problems [45, 46], some differentiate between 0, 1-2 (infrequent), and 3 or more (recurrent) UTIs per year [25] and other consider 0-2 and 3 or more UTIs per year as sporadic and recurrent UTIs, respectively [47]. Whatever definition, a subpart of the population does consistently not experience UTIs when reported on a yearly basis. There may also be a difference in incidence rates between self-reported UTIs and those medically documented in retrospective and prospective studies [17, 20, 25]. Altogether, such heterogeneous UTI definitions seriously hamper the clinical and research efforts and may over- or underscore the importance of various risk factors.

### 3.2. Patient Perspective on UTIs

CIC is widely used for the urological management of neurogenic bladders, and UTI is the most frequently reported and challenging complication [48]. The diagnosis of UTI in the general population is not generally applicable to individuals with SCI, SB, or CE due to loss of sensation and a neurogenic bladder requiring alternative bladder emptying like CIC. The common symptoms include increased bladder spasticity, new or worsening urinary incontinence, autonomic dysreflexia, and foul-smelling urine.

The NIDRR consensus statement on the prevention and management of UTI among people with SCI listed a set of signs and symptoms as suggestive of UTI [44]. The validity, accuracy, and predictive value of these signs and symptoms were evaluated during the first 3 months of a 1-year-long randomised controlled CIC-catheter trial (RCT) in chronic SCI patients [20, 49]. Subjects were able to predict their own UTI with an accuracy of 66%, and with positive and negative predictive values of 33% and 83%, respectively. Okamoto [50], evaluating CIC-users in general, presented findings along the same line, underlining the CIC-user’s insecurity regarding the interpretation of their UTI signs and symptoms. Self-reported UTIs should hence be interpreted with care.

### 3.3. Rehabilitation Centres’ Perspective on UTIs

A questionnaire-based survey of 13 German-speaking SCI rehabilitation centres sheds light on the variability of handling the UTIs in SCI patients (irrespective of bladder management), both with respect to diagnosing as well as treating a UTI [51]. The criteria for accepting a UTI urine analysis as positive differed and the symptomatic treatment was started with “fever without other causes” as the most frequently symptom irrespective of leucocyte count. These finding underlines both the impact of the personal experience of the treating physician and the paucity of published evidence.

When evaluating the evidence on UTI risk factors in neurogenic CIC-users, issues like heterogenic UTI definitions, uncertainty of patients’ self-reported data, and significant differences between medical evaluation and treatment of UTIs could profoundly influence the level of
importance of the separate risk factors. Additionally, the importance of specific risk factors may differ between individual patients.

**4. The Model: General Conditions**

**4.1. High Intravesical Pressure/Impaired Bladder Compliance.** With any spinal cord injury, the disruption of the normal somatic and autonomic neurological control of bladder causes bladder dysfunction; in higher suprasacral injuries, a micturition reflex may emerge after the acute phase to cause detrusor overactivity and sometimes detrusor-sphincter dysynergia (DSD) with ineffective bladder emptying and clinical significant large postvoid residual volumes. Lesions in the lumbosacral area affecting the autonomic nuclei may cause detrusor hypocontractility with bladder over-filling and voiding inability. All SCI and most of the SB patients have bladder dysfunction; it is common in MS, and if disease duration is above 10 years, up to 80% of the MS patients have bladder symptoms [11].  

Individuals with high intravesical pressures and impaired bladder compliance are more prone to UTI’s than those with low intravesical pressure and high capacity bladder that it is emptied periodically by IC. The risk factors are the high intravesical pressures in the first case and the risk of bladder over-distention in the other case [52].

---

**Table 1: Definitions for catheter-associated urinary tract infection.**

| **2017/18 Guidelines on Neuro-Urology of the European Association of Urology (EAU)** [4]. | **2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America (IDSA) [41].** |
|---|---|
| +Blok et al. EAU guidelines on Neuro-Urology 2015 [40]. |  |
| Signs and/or symptoms accompanied by laboratory findings of a UTI (bacteriuria, leukocyturia*, and positive urine culture). Significant bacteriuria in persons performing IC is present with >10⁵ colony-forming units (cfu)/mL, >10⁴ cfu/mL in clean-void specimens*, and any detectable concentration in suprapubic aspirates. The most common signs and symptoms in those with neuro-urolological disorders are fever, new onset or increase in incontinence, including leaking around an indwelling catheter, increased spasticity, malaise, lethargy or sense of unease, cloudy urine with increased urine odour, discomfort or pain over the kidney or bladder, dysuria, or autonomic dysreflexia. | Symptoms or signs compatible with UTI with no other identified source of infection along with ≥10⁵ cfu/mL of ≥1 bacterial species in a single catheter urine specimen or in a midstream voided urine specimen from a patient whose urethral, suprapubic, or condom catheter has been removed within the previous 48 h. |

---

**ISCoS Urinary Tract Infection Basic Dataset [42].**

(i) New onset of symptoms accompanied by laboratory findings (bacteriuria, leukocyturia and positive urine culture) of a UTI.  
(ii) Symptoms: fever, urinary incontinence/failure of control or leaking around the catheter, spasticity, malaise, lethargy or sense of unease, cloudy urine, malodorous urine, pyuria/leukocyturia, back pain, bladder pain, dysuria, autonomic dysreflexia (AD).  
(iii) A clean-catch midstream technique from an immediately installed urine catheter. Any positive culture should be reported. The clinical Microbiological Laboratory (CML), 10³ CFU ml⁻¹ is a reliable finding with standardized inoculation with 10 µl urine.

*Leucocyturia is defined as 10 or more leucocytes in centrifuged urine samples per microscopic field (400×). In the catheterised patient, pyuria is not diagnostic of CA-bacteriuria or CAUTI, and the presence, absence, or degree of pyuria alone does not, by itself, differentiate catheter-associated asymptomatic bacteriuria from CAUTI. However, the absence of pyuria in a symptomatic catheterised patient suggests a diagnosis other than CAUTI.  

---

4 Advances in Urology
due to large urine volumes [29]. Lapides suggested that “it was logical to assume that maintenance of a good blood supply by prevention of vesical overdistension and elevated intravesical pressures would combat infection” [54]. A 7-year prospective study showed that a mean volume of each catheterisation >400 ml is linked UTI [45].

4.2. Host Deficiencies (Impaired Immune System). Altered intrinsic defence mechanisms and immune suppression after spinal injuries augment the risk for UTIs possibly due to changes in the microbial flora, immunological deficiencies [56], and alterations in the bladder wall and its urothelium [29, 57]. Such conditions are presently not readily modifiable in daily clinical practice. Apart from the local injury in the spinal cord, patients may develop a variety of complications characterized by multiple-organ dysfunction such as lung injury, cardiovascular disease, liver and kidney damage, and increased susceptibility to infection. The damage to the autonomic nerve system (ANS) leads to a general immune dysfunction through the loss of neural innervation of lymphoid organs.

4.3. Bowel Dysfunction. The distal colon and urinary bladder have a similar function of the storage and evacuation of faeces and urine, and there is a joint peripheral innervation of both viscera, through the hypogastric, pelvic, and pudendal nerves [58]. It is therefore not unexpected that spinal cord injuries also affect colorectal motility, transit times, and bowel emptying, leading to constipation, faecal incontinence, or a combination of both. When treating neurogenic bowel dysfunction in terms of faecal incontinence and constipation with transanal irrigation, a more than three-fold reduction of UTI incidence rates was documented [59, 60]. The reason for this UTI reduction is unknown; it could be speculated that fewer episodes of faecal incontinence causes less genitourinary bacterial contamination or, given the role of the kidneys and bladder in filtration and storage of waste, respectively, microbial profiles and microbial metabolites of the gut might influence the urinary microbiota, and alterations might affect urinary urothelium [61]. Further, rectal impaction has been suggested to cause lower urinary tract symptoms (LUTSs) by mechanically to impede bladder emptying [62]. Hence, an optimal bowel treatment of constipation and incontinence should go hand in hand with bladder management.

4.4. Diabetes. Diabetes per se bears a 2- to 3-fold risk for UTI compared to nondiabetic controls, and the severity is usually more severe and carries worse outcomes [63, 64]. A large cross-sectional Canadian Community Health Survey compared the prevalence of type 2 diabetes in the SCI population with that of a nonSCI population [65]. They found, regardless of the variables included in the models, an approximately 2-fold increased odd for type 2 diabetes in the SCI population, which is not explained by known risk factors for type 2 diabetes. In other words, unexplained occurrences of UTI may be related to undiagnosed diabetes.

4.5. Age and Gender. It is inconclusive whether age or gender plays a major role for the UTI risk in the neurogenic population; some studies suggest a slightly higher UTI rate for females [25, 45], whereas older studies reported conflicting results [28]. A recent, retrospective chart review of 194 SB patients (median age 22 years, range 8 months–58 years) found that increasing age was associated with decreasing odds of UTI by 7% per year, independent of gender [46]. As the authors could not verify compliance with the recommended CIC frequency or technique, age and maturity may have impacted the patient’s ability to manage their bladder emptying and hence risk of UTI.

5. The Model: Local Urinary Tract Conditions

5.1. Bacterial Virulence. The development of UTIs in the neurogenic bladder relies on a balance between bacterial virulence and local host factors. When the ability to locally fight the infection is compromised, the uropathogens have better access to the urinary tract and their washout of the bladder is lost [29]. Further, upon alteration of protective flora and changes in the urothelium and bladder wall after injury may let the uropathogens inside the urinary tract more easily adhere to the urothelium and invade the bladder wall [57, 66]. All such events may end up in UTIs; however, investigation and treatment of these factors are at present on an experimental level.

Antibiotics may also interfere with the protective flora. A study in 70 women with UTIs showed that the original lactobacillus population had not been restored after treatment in most patients; rather, the uropathogens dominated the flora [67]. A similar condition could be relevant for the microbiome in the bladder.

The strategy of supporting the host bacterial flora by adding nonpathogenic bacteria have been investigated in a couple of small studies [68, 69]. Inoculation of nonpathogenic bacteria (mostly E. coli) into the bladder showed sufficient colonization rates of the inoculated pathogenic bacteria and significant reductions in UTI frequency. It appears that this approach could be useful, although there is still insufficient evidence to support the use of bacterial interference for UTI prevention in daily practice [4, 42].

5.2. Previous UTIs. Previous UTIs are accepted as a risk factor because they render the bladder urothelium into a chronic, inflammatory condition more susceptible to re-infection. A 7-year prospective study of CIC-users found two predictive factors; patients with high UTIs at the start of the study also had high UTI rates at the end of the follow-up period and high UTI rates were linked to development of high catheterisation volumes [45].

5.3. Botulinum Toxin A Injections. Detrusor treatment with Botulinum Toxin A injections efficiently combats neurogenic detrusor overactivity [70] but there is controversy about the UTI rates postinjection [43] and whether there should be antibiotic coverage for the therapeutic sessions [71]. Data from a single SCI rehabilitation centre,
comprising 1104 patients with at least 3 years follow-up, found that the odds of a UTI increased 10-fold for those receiving botulinum detrusor injections [6].

5.4. Urodynamic Investigations. Urodynamic investigations are by far the most commonly used method for bladder evaluation, it is believed to increase the risk for UTIs, and therefore, the American Urological association suggests that high risk patients with neurogenic lower urinary tract dysfunction should receive antibiotic prophylaxis for UTI prophylaxis [72]. Data from a recent SCI study found that a history of UTI within the past 4 weeks prior to the urodynamic investigation increased the risk for a new UTI [73].

5.5. Bladder and Kidney Stones. Bladder and kidney stones are well-known risk factors for UTIs and evolve through two mechanisms; infection stones caused by urease-producing Gram-negative organisms and metabolic stones that passively trap bacteria from coexistent UTIs [74, 75]. By clinical experience, stones may stimulate the detrusor overactivity and hence the intravesical pressures, related to recurrent UTIs. In very rare occasions a foreign body, e.g. a hair, inserted through catheterisation, provides the basis for stone formation [76].

5.6. Postvoid Residual Urine Caused by Bladder Shapes. Merrit [77] originally described a correlation between postvoid volume and UTI frequency based on 105 SCI patients, which, however, could not be reproduced in a small-scale study in 12 SCI subjects [78]. Smaller volumes (<50 ml) in CIC-users did not predispose to UTIs [47]. Despite lack of clear evidence for a cut-off level, increased amounts of postvoid residual urine (>100 ml) is an accepted risk factor for UTI in the neurogenic population [62]. The reasons for experience residual urine could be many including anatomical bladder abnormalities, not proper education of patient, handling of IC catheter, and product choice (IC catheter).

Anatomical abnormalities that limit complete bladder emptying (e.g., prostatic impression, bladder diverticulum or trabeculated “Christmas tree bladders”) are conditions in which lagoons of urine are difficult to empty during catheterisation and so potentially provide a nidus for bacterial proliferation. There are no studies addressing these conditions, but it appears logical to accept such as risk factors. Such bladders may also have altered compliance, contributing to the UTI risk.

6. The Model: User Compliance/Adherence

In relation to UTI, compliance in this article describes the extent to which a CIC-catheter user adheres to the medical advice given by their treating health-care provider as to prevent UTIs [79] (compliance in this review does not consider reasons for discontinuing CIC management). As noted by Shekelle et al. [28], there was at that time a “paucity of data on the independent effect of psychosocial, behavioural, or hygienic factors on the risk of UTI in people with SCI”. Nothing seems to have changed substantially with respect to the evidence base of these factors, but it is generally recognized that factors like misconceptions, anxiety, embarrassment, and poor confidence can be barriers to CIC, which can be worsened by physical disabilities, e.g., dexterity or visual impairment [80, 81].

In the context of performing CIC it should also be taken into account that: (1) patients with neurodegenerative disorders often present with various levels of cognitive dysfunction; (2) psychiatric diagnoses, including depression and anxiety, are not unusual among individuals with relevant neurological diseases; (3) polypharmacy is not unusual in these patients and some medicines do impose a high anticholinergic burden. Cognitive function should be routinely assessed in neuromotorlogists to provide individualized counselling on IC technique.

6.1. Voiding Frequency. Voiding frequency and urine volume (two sides of the same coin) as infrequent voiding, result in larger bladder volumes that may over distend the bladder and so increase the risk for UTI. A survey of Canadian SCI patients found that voiding frequency was inversely related to number of UTIs, with one daily catheterisation having the highest UTI rate in a univariable analysis [25]. In a study of Paralympic athletes who catheterised from 1 to 10 per day (average 6±2 times), the frequency of daily catheterisations was not related to the frequency of UTIs, p = 0.07 [21]. As mentioned above, the catheterisation volume must be kept below 400 ml [45].

6.2. Fluid Intake. Poor fluid intake is generally considered as a risk [82] for UTIs in neurogenic bladder disease, and a low fluid intake has been associated with an increase in urine osmolality and acidity, which may predispose to UTIs [83]. In this context, the absence of diurnal variation of antidiuretic hormone levels in spinal cord injured subjects could play a role for adequate fluid intake [84]. All in all, empirical evidence for role of fluid intake for UTI prevention in the neurogenic population is scarce, and therefore, it is not possible to draw any firm evidence-based conclusions about daily fluid intake [83]. However, general medical experience supports the intake of daily adequate amounts of fluids, which recently was supported by a clinical study showing that increased water intake prevents recurrent cystitis in premenopausal women [85].

6.3. Nonhygienic Procedures. The Canadian survey of 935 SCI patients living in community determined CIC hygienic practices found, based on a univariate model, that genital and peritoneal cleaning was associated with reduced UTI rate as was self-catheterisation compared to catheterisation by others [25]. Wyndaele et al. [86] compared the results in 25 paraplegic patients started on CIC 35 days postinjury with 48 paraplegic patients catheterised postinjury by nurses with a nontouch technique and found comparable UTI rates in the two groups. The EAUN guidelines strictly encourages the
no-touch techniques; however, no evidence for the no-touch technique on the UTI rate is given [81]. For comparison, a study was carried out on simulation models, evaluating the difference between classical sterile procedure and a no-touch procedure in hospital settings [87]. The no-touch procedure caused a lower amount of sterility errors and shorter duration of the intervention compared with the classical method. Whether less sterility errors translates into a lower rate of UTIs remains to be shown.

The basic importance of hand washing for prevention of infection was already emphasised by Semmelweis and Koch [88, 89]. The various guidelines also underline that patients who self-catheterise should disinfect or wash hands thoroughly with water and soap before catheterisation [82, 90–92]; however, it appears that the recommendations are based on experience from hospital setting and not on clinical evidence form community settings. A recent survey of self-reported habits amongst community dwelling SCI subjects showed that only half of the subjects washed hands as recommended, but no relationship was found with either occurrence or frequency of UTIs [93].

Obesity may be independently associated with UTIs [94, 95], particularly prominent in very obese men (BMI > 50) but less so for women. No data specific for the neurogenic population are available. It could be speculated that obese subjects have difficulty with bowel hygiene and as such are at increased risk of vulvovaginal symptoms and UTI.

Self-catheterisation versus catheterisation by others was associated with a significantly reduced UTI rate in a Canadian national survey of intermittent catheterisation practices following SCI [25]. Similar, after commencement of IC in a SB population, it appeared that IC self-catheterisation prompted a greater reduction of UTI than assisted IC [96].

6.4. Insufficient Education. Guidelines to IC recommend that comprehensive training on IC technique should be provided to neurourological patients [4, 78, 82], but adherence to CIC technique as recommended by health-care personnel was just followed by 76% of responders [93]. A RCT examined the impact of an educational program on UTI frequencies [32]; the educational intervention resulted in less bacteriuria and a nonsignificant trend toward fewer symptom reports and antibiotic treatment episodes as well as decreased UTIs. However, for individuals with recurrent UTIs, increased knowledge may lead to increased perceptions of the severity of UTIs. Education for spinal cord injured athletes suggests that education may be advantageous [92] but a systematic review of educational programs did not detect a substantial beneficial effect [97]. A shortcoming of the previous studies did not assess quality of educational initiatives, as no objective feedback was obtained from the patients. In a European initiative undertaken by eight rehabilitation centres in Norway, France, and Italy, it was shown that a good education programme can improve adherence to IC during the first year at home (99 vs. 83% for the Education Programme and control groups, respectively; \(p < 0.05\)) [98]. From a clinical point of view, comprehensive training on IC technique should be provided to neurourological patients. Whenever a patient presents with UTI, IC technique and frequency must be reviewed [82].

6.5. Postvoid Residual Urine due to Incorrect Handling. The causes for residual urine could be many fold, as described previously. In particular, removal of the intermittent catheter before complete bladder emptying is frequently encountered in clinical practice and is considered as a risk for UTIs. This procedure should be included in the training of patients.

6.6. Residence Country and Social Support System (Reimbursement). The differences in patterns of care are closely related to socioeconomic status and resources of the geographic area [44, 99]. CIC is well established in developed countries and seems to be part of standard patient care in the larger Asian and South American countries [100]. In the same way, low UTI incidence rates are related to developed countries, whereas higher rates are detected in less developed areas [21]. These findings underline the unmet needs present in many countries.

The importance of compliance and lifestyle for UTI prevention in community living subjects is not based on solid clinical evidence but rather driven by economic conditions, guideline recommendations, health-care personnel directions and patients own habits based on their individual disabilities and physical surroundings. The guidance given varies between institutions, regions, and countries, heavily influenced by social security systems and reimbursement schedules. Evaluation of IC regimen and individual costs related to IC should be done to improve nationwide control of cost. However, feasibility is difficult to evaluate and as cost.

7. The Model: Intermittent Catheters

7.1. Bacteria Inserted by Product and No Urethral Rinsing. Intermittent catheterisation per se is an important etiological risk factor for UTI in the neurogenic bladder [29]. It allows bacteria from the lower urethral region to be deposited directly into the bladder and cannot create the mechanical rinsing of the bladder that occurs during normal voiding. Additionally, nonhygienic intermittent catheterisation practices can introduce bacteria into the urinary tract. The use of no-touch catheter technique, which includes use of a urinary catheters without touch by the user’s hand, like a nontouch sleeve and insertion tip has been shown to reduce the risk. Clinical studies suggest that use of a no-touch catheter is associated with a 30% reduction in bacteriuria and general low bacteriuria levels [16, 101]; however, data are based on few patients and bacterial counts only.

A hospital study reported on a no-touch catheter and technique with 35% less infection (UTIs not defined) per admission when compared to a retrospective, very different control group [102]. Both studies are therefore not providing clinical evidence for the benefit of a no-touch catheter system. In a 2 × 2 weeks crossover study of a new no-touch sleeve system compared to a conventional catheter, five UTIs were reported, but without information about in which
group they occurred [103]. Interestingly, in the Canadian survey, there was no difference in UTI incidence rate if catheters were disinfected between use or not [25].

In summary, the positive influence of catheter design is controversial, but overall, the present evidence suggests beneficial use of hydrophilic catheters for CIC management.

7.2. Urethral and Bladder Trauma from Product. Chemical and physical properties of the catheter surface are important when looking at risk for creating trauma from product. Compared to gel lubrication, catheters with hydrophilic coatings caused significantly less urethral trauma (haematuria), less removal friction, and less pain [104]. This could be related to the clinical experience that lubricating catheters with a gel is insufficient to protect the urethra from injury, as the lubricant is lost upon entering the urethral meatus [105]. The osmolarity of hydrophilic catheter coatings was found to reduce both removal friction and urethral trauma (haematuria) during catheterisation since a hyperosmolar coating appears gentler to the urethral mucosa due to its higher water content [106]. A study of urethral cytology in SCI patients performing CIC demonstrated a significantly lower inflammatory response in patients using hydrophilic catheters compared to uncoated catheters [107]. The data demonstrates that single-use hydrophilic catheters have properties that minimize urethral trauma.

Urethral strictures are a consequence of long-term use of CIC [6, 108]. The authors found during an observation period of 5-6 years a stricture rate of 25% and 19%, of which 36% and 21% required urethrotomy, respectively. Difficult and traumatic catheterisations may cause injuries ranging from a mucosal tear to more serious false passages, which are associated with UTIs and strictures and subsequently may require surgical management [109]; strictures may make future catheterisations difficult and cause repeated injury and UTIs [110]. Careful education of catheterisation technique and selection of the proper catheter is fundamental [111].

Patterns of use. The 2014 Cochrane review by Prieto et al. [112] “Intermittent catheterisation for long-term bladder management” was one of the leading documents concerning bladder management in the neurogenic population. The opinion expressed in the paper however concerned many clinicians and led to an independent reanalysis of the Cochrane data [113]; consequently, the Cochrane publication was withdrawn due to their erroneous data selection, data extraction, data analysis, and use of outdated UTI definition. The reanalysis could not detect any significant differences in the UTI incidence rates between aseptic vs. other techniques and single vs. multiple use of catheters due to the small number of participants and short or unclear duration of trials; it was not possible to draw final conclusions. In contrast to the Cochrane review, a significant difference favouring use of hydrophilic catheters vs. other catheters was detected.

The studies that were eligible for inclusion in the meta-analyses were executed in in-patient hospital/rehabilitation centres and/or community environments and included in total 502 patients, essentially evaluated over a few months (hospital/rehab centres: 209 patients during a median study period of 12 weeks; hospital/rehab and subsequent community residence: 123 SCI patients SCI during a 52-week study period; community: 56 SCI patients during 52 weeks and 82 SB children during a median study period of 16 weeks; 32 male patients with enlarged prostates were studied during a 6-week period). The two long-term trials of 52 weeks in SCI patients showed comparable results. De Ridder et al. [17] performed the trial in 123 patients during rehabilitation and subsequent community residence and found significantly less UTIs associated with hydrophilic catheters than with uncoated (single use). Cardenas et al. [20] in 56 community dwelling patients also documented significantly less UTIs associated with hydrophilic than with uncoated catheters (single use).

As stated by the authors of the meta-analysis, due to the inadequate numbers of participants and the predominantly short trial duration, additional trials are necessary to conclude about catheterisation technique and catheter usage. Based on the present level of evidence, the authors recommended single use hydrophilic catheters.

Since the analyses, based on data collected until 2014, several new studies have emerged. Rognoni et al. [114] also challenged the outcome of previously published meta-analyses and compared complication rates in terms of UTI and urethral trauma/haematuria related to hydrophilic coated catheters vs. nonhydrophilic urinary catheters. The meta-analyses exploring UTI frequencies showed a 16% lower risk ratio associated with hydrophilic catheters in comparison to standard ones (95% CI, 6–25%, p = 0.003) and so corroborate the benefits of hydrophilic catheters.

Kiddoo et al. [115] studied the UTI incidence rate in a crossover trial (2 × 24 weeks) of single use hydrophilic catheters vs. multiple use polyvinylchloride catheters in 66 SP children. They found a statistically significant lower person week of UTI (defined as positive leucocyte dipstick and self-reported fever/pain/increased incontinence or cloudy/odorous urine) in multiple use, but no differences with respect to fever, antibiotic use visits to physicians, missed activities, and positive dipstick for leucocytes and haematuria. In other words, there was no difference in febrile or antibiotic-treated UTIs between use of these two catheter types.

7.3. Postvoid Residual Urine due to Product Design. Choosing the appropriate intermittent catheter tailored to the patient is important to avoid residual urine; this includes, e.g., choosing a catheter of a proper length with proper placement of the eyelets, considering catheter stiffness, and adapting catheter handling to these features.

8. Discussion

The purpose of this review was several folds: to remind clinicians that the correct diagnosis and thereby treatment/management of UTI/bacterial contamination in the
ANLUTD patient population is challenging and far from simple; to update and discuss the UTI risk factors associated to IC in community settings; and to provide a simple, holistic, and useful risk factors model that can be used by the clinician for daily practice and thereby optimise the modification of these risk factors to the benefit of these patients.

A basic prerequisite is the alignment on the definition of a UTI. As described, many definitions are used in the real-world setting and complicate the understanding and comparability of results. Various medical societies have suggested their UTI definition, but it is imperative from a research perspective that a unified global UTI definition be agreed upon in order to objectively study current and future diagnostic and therapeutic treatment options for UTI.

Overall, the evidence for many of these risk factors role for the development of UTIs are limited and the impact of the personal experience of the clinicians may affect the handling of these risk factors, which should not prevent deciding on specific diagnosis, like UTI, based on available guidelines.

Some of the risk factors have with relative certainty causality roles for UTIs, like high intravesical pressure, the coexistence of a detrusor external-sphincter system dysfunction, catheter and catheterisation procedures, and nonadherence to CIC recommendations. Other proposed risk factors, like Botox injections, urodynamic investigations, or patient education, may to a higher degree be based on expert opinions. Future research is clearly necessary for a better understanding of the impact of a specific risk, both in terms of evaluating a direct causality as well as estimating their importance in real-life situations, where other factors additionally can modify the risk.

Individual conditions for each patient also play an important role and the clinicians should take all this individual variability into account. Each new UTI should trigger a holistic assessment of the patient’s situation including overall health, mobility, bladder urodynamic situation, and bowel function. Further, the patients’ cognitive function should be assessed to determine the correct understanding of IC procedures and compliance issues. Recurrent UTIs warrant additional investigation and assessment, which may involve imaging, flexible cystoscopy, and video-urodynamic assessment. In case of carer-assisted IC, procedure-related and educational approaches may be necessary.

The importance of catheter properties appears to be of relevance. The risk related to different IC-catheter types, like uncoated catheters, reuse catheters, or single use, hydrophilic ready-to-use catheters have been thoroughly discussed in the recent years; meta-analyses have provided some indications that hydrophilic catheters appear to be linked to the lowest UTI risk [113, 114]. This reflects the physiological common sense that less trauma to urethra and bladder is likely to leads to less UTI. Catheters ready-to-use (hydrophilic coated catheter) appear to cause less constraints for daily use in patients suffering from debilitating conditions like SCI, SB, or MS. Due to the heterogeneity of catheter-users, it can be anticipated, that a hydrophilic, ready-to-use catheter takes away the user’s variability in use of the product. This product safety feature of ready-to-use catheters in essence improves product safety by decreasing individual variability in its use.

9. Conclusion

There is a need for alignment of the definition and diagnosis of UTI. It may be done disease per disease or more generally. Even with less complications than other bladder management methods, CIC still expose ANLUTD patients with a high risk of UTIs, a condition associated with increased morbidity and mortality in this patient group. There is a paucity of evidence describing the UTI risk profile, and well-designed clinical trials are warranted to provide the clinician a better platform for adequate management of the UTI risk profile to the benefit of these patients. Guidelines, when available, should be adhered to.

Appendix

Intermittent catheterisation (IC) is defined as drainage of the bladder or a urinary reservoir with subsequent removal of the catheter mostly at regular intervals. Clean IC (CIC): this involves use of a clean technique. This implies ordinary hand and genital washing techniques and use of disposable or cleansed reusable catheters [1].

Aseptic IC: this implies genital antisepsic preparation and the use of sterile (single use) catheters and instruments/gloves in a designated clean area.

Sterile IC: complete sterile setting, including genital antisepsis, sterile gloves, forceps, gown, and mask.

No-touch technique IC: this was introduced as an easier way for the patient to perform self-intermittent catheterisation with a ready-to-use catheter (prelubricated catheter, usually a hydrophilic catheter).

Conflicts of Interest

Michael Kennelly, Nikesh Thiruchelvam, Márcio Augusto Averbeck, Charalampos Konstantinidis, and Emmanuel Chartier-Kastler are all part of the Coloplast Neurology Advisory Board.

Acknowledgments

This study was financially supported by Coloplast A/S, Denmark, by a fee to Birte Petersen Jakobsen for manuscript writing and editing. Article processing charges was also covered by Coloplast A/S, Denmark.

References

[1] J. B. Gajewski, B. Schurch, R. Hamid et al., “An International Continence Society (ICS) report on the terminology for adult neurogenic lower urinary tract dysfunction (ANLUTD),” Neurourology and Urodynamics, vol. 37, no. 3, pp. 1152–1161, 2018.

[2] K. J. Weld and R. R. Dmochowski, “Effect of bladder management on urological complications in spinal cord
injured patients," Journal of Urology, vol. 163, no. 3, pp. 768–772, 2000.

[3] M. Söllker, B. Blok, D. Castro-Diaz et al., “EAU guidelines on neurogenic lower urinary tract dysfunction,” European Urology, vol. 56, no. 1, pp. 81–88, 2009.

[4] B. Blok, D. Castro-Diaz, G. del Popolo et al., EAU Guidelines on Neuro-Urology, European Association of Urology, Arnhem, Netherlands, 2017, https://uroweb.org/guideline/neuro-urology/.

[5] J. J. E. Adriaansen, F. W. A. van Asbeck, M. Tepper et al., “D. J. M. K. De Ridder, K. Everaert, L. G. Fernandez et al., “Differences in urinary tract infections in male and female spinal cord injury patients on intermittent catheterization,” Spinal Cord, vol. 33, no. 2, pp. 69–72, 1995.

[7] J. Krebs, J. Wöllner, and J. Pannek, “Urethral strictures in men with neurogenic lower urinary tract dysfunction using intermittent catheterization for bladder evacuation,” Spinal Cord, vol. 53, no. 4, pp. 310–313, 2015.

[8] C. R. de Almeida, K. Carneiro, R. Fiorelli, M. Orsini, and R. M. P. Alvarenga, “Urinary dysfunction in women with multiple sclerosis: analysis of 61 patients from rio de janeiro, Brazil,” Neurology International, vol. 5, no. 4, p. 23, 2013.

[9] V. Kalsi and C. J. Fowler, “Therapy insight: bladder dysfunction associated with multiple sclerosis,” Nature Clinical Practice Urology, vol. 2, no. 10, pp. 492–501, 2005.

[10] D. McClurg, C. Bugge, C. Elders et al., “Factors affecting continuation of clean intermittent catheterisation in people with multiple sclerosis: results of the COSMOS mixed-methods study,” Multiple Sclerosis Journal, vol. 27, no. 3, pp. 231–237, 2018.

[11] D. B. Clayton, J. W. Brock 3rd, and D. B. Joseph, “Urologic management of spin bs,” Developmental Disabilities Research Reviews, vol. 16, no. 1, pp. 88–95, 2010.

[12] X. Gamé, C. J. Fowler, and J. N. Panicker, “Neuropathic bladder dysfunction,” Trends in Urology, Gynaecology & Sexual Health, vol. 15, no. 1, pp. 23–28, 2010.

[13] S. Sarica, Y. Akkoc, H. Karapolat, and H. Aktug, “Comparison of the use of conventional, hydrophilic and gel-lubricated catheters with regard to urethral micro trauma, urinary system infection, and patient satisfaction in patients with spinal cord injury: a randomized controlled study,” European Journal of Physical and Rehabilitation Medicine, vol. 46, no. 4, pp. 473–479, 2010.

[14] R. B. King, C. E. Carlson, J. Mervine, Y. Wu, and G. M. Yarkony, “Clean and sterile intermittent catheterization methods in hospitalized patients with spinal cord injury,” Archives of Physical Medicine and Rehabilitation, vol. 73, no. 9, pp. 798–802, 1992.

[15] A. Giannantoni, S. M. Di Stasi, G. Scivoletto, G. Virgili, S. Dolci, and M. Porena, “Intermittent catheterization and infection in spinal cord injured patients,” Journal of Urology, vol. 169, no. 3, pp. 957–968, 2018.

[16] C. J. Bennett, M. N. Young, and H. Darrington, “Differences in urinary tract infections in male and female spinal cord injury patients on intermittent catheterization,” Spinal Cord, vol. 33, no. 2, pp. 69–72, 1995.

[17] D. J. M. K. De Ridder, K. Everaert, L. G. Fernández et al., “Intermittent catheterisation with hydrophilic-coated catheters (SpeediCath) reduces the risk of clinical urinary tract infection in spinal cord injured patients: a prospective randomised parallel comparative trial,” European Urology, vol. 48, no. 6, pp. 991–995, 2005.

[18] D. D. Cardenas, K. N. Moore, A. Dannels-McClure et al., “Intermittent catheterization with a hydrophilic-coated catheter delays urinary tract infections in acute spinal cord injury: a prospective, randomized, multicenter trial,” PM&R, vol. 3, no. 5, pp. 408–417, 2011.

[19] C. E. Anderson, “Bladder emptying method is the primary determinant of urinary tract infections in patients with spinal cord injury: results from a prospective rehabilitation cohort study,” BJU International, vol. 123, no. 2, pp. 342–352, 2018.

[20] D. D. Cardenas, J. M. Hoffman, and Hoffman, “Hydrophilic catheters versus noncoated catheters for reducing the incidence of urinary tract infections: a randomized controlled trial,” Archives of Physical Medicine and Rehabilitation, vol. 90, no. 10, pp. 1668–1671, 2009.

[21] A. Krassioukov, J. J. Cragg, C. West, C. Voss, and D. Krassioukov-Enns, “The good, the bad and the ugly of catheterization practices among elite athletes with spinal cord injury: a global perspective,” Spinal Cord, vol. 53, no. 1, pp. 78–82, 2015.

[22] K. N. Moore, D. Kiddoo, B. Sawatzky et al., “Randomised crossover trial of hydrophilic single use versus PVC multiuse catheters for CIC in children with neural tube defects (spina bifida) (Abstract number 171),” Neurorehabilitation and Neurological Rehabilitation, vol. 32, no. 6, pp. 760–761, 2013.

[23] A. E. De Ruz, E. G. Leoni, and R. H. Carrera, “Epidemiology and risk factors for urinary tract infections in patients with spinal cord injury,” Journal of Urology, vol. 164, pp. 1285–1289, 2000.

[24] J. M. Vapnek, F. M. Maynard, and J. Kim, “A prospective randomized trial of the LoFric hydrophilic coated catheter versus conventional plastic catheter for clean intermittent catheterization,” Journal of Urology, vol. 169, no. 3, pp. 994–998, 2003.

[25] M. G. Woodbury, K. C. Hayes, and H. K. Askes, “Intermittent catheterization practices following spinal cord injury: a national survey,” Canadian Journal of Urology, vol. 15, no. 3, pp. 4065–4071, 2008.

[26] H. Fisher, Y. Oluboyede, T. Chadwick et al., “Continuous low-dose antibiotic prophylaxis for adults with repeat urinary tract infections (AntIC): a randomised, open-label trial,” Lancet Infectious Diseases, vol. 18, no. 9, pp. 957–968, 2018.

[27] J. Krebs, J. Wöllner, and J. Pannek, “Risk factors for symptomatic urinary tract infections in individuals with chronic neurogenic lower urinary tract dysfunction,” Spinal Cord, vol. 54, no. 9, pp. 682–686, 2016.

[28] P. G. Shekelle, S. C. Morton, K. A. Clark, M. Pathak, and B. G. Vickrey, “Systematic review of risk factors for urinary tract infection in adults with spinal cord dysfunction,” Journal of Spinal Cord Medicine, vol. 22, no. 4, pp. 258–272, 1999.

[29] P. Vasudeva and H. Madersbacher, “Factors implicated in pathogenesis of urinary tract infections in neurogenic bladders: some revered, few forgotten, others ignored,” Journal of Urology, vol. 166, no. 2, pp. 258–272, 2001.

[30] E. J. Lucas, C. Baxter, C. Singh et al., “Comparison of the microbiological milieu of patients randomized to either hydrophilic or conventional PVC catheters for clean intermittent catheterization,” Journal of Pediatric Urology, vol. 12, no. 3, pp. 172.e1–178.e8, 2016.
[31] K. N. Moore, J. Burt, and D. C. Voaklander, “Intermittent catheterization in the rehabilitation setting: a comparison of clean and sterile technique,” Clinical Rehabilitation, vol. 20, no. 6, pp. 461–468, 2006.

[32] D. D. Cardenas, J. M. Hoffman, E. Kelly, and M. E. Mayo, “Impact of a urinary tract infection educational program in persons with spinal cord injury,” Journal of Spinal Cord Medicine, vol. 27, no. 1, pp. 47–54, 2004.

[33] A. P. Cameron, G. M. Rodriguez, A. Gursky, C. He, J. Q. Clements, and J. T. Stoffel, “The severity of bowel dysfunction in patients with neurogenic bladder,” Journal of Urology, vol. 194, no. 5, pp. 1336–1341, 2015.

[34] R. J. Madden-Fuentes, E. R. McNamara, J. C. Lloyd et al., “Variation in definitions of urinary tract infections in spina bifida patients: a systematic review,” Pediatrics, vol. 132, no. 1, pp. 132–139, 2013.

[35] M. A. Averbeck, A. Rantell, A. Ford et al., “Current controversies in urinary tract infections: ICSI-RS 2017,” Neurourology and Urodynamics, vol. 37, no. S4, pp. S86–S92, 2018.

[36] T. Linssenmeyer and A. Oakley, “Accuracy of individuals with spinal cord injury at predicting urinary tract infections based on their symptoms,” Journal of Spinal Cord Medicine, vol. 26, no. 4, pp. 352–357, 2003.

[37] G. Bonkat, R. Pickard, R. Bartoletti et al., EAU Guidelines on Urological Infections, European Association of Urology, Arnhem, Netherlands, 2018.

[38] L. E. Nicolle, “Urinary tract infections in patients with spinal injuries,” Current Infectious Disease Reports, vol. 16, no. 1, p. 390, 2014.

[39] J. Salomon, P. Denys, C. Merle et al., “Prevention of urinary tract infection in spinal cord-injured patients: safety and efficacy of a weekly oral cyclic antibiotic (WOCA) programme with a 2 year follow-up—an observational prospective study,” Journal of Antimicrobial Chemotherapy, vol. 57, no. 4, pp. 784–788, 2006.

[40] B. Blok, D. Castro-Diaz, G del Popolo et al., Guidelines on Neuro-Urology, European Association of Urology, Arnhem, Netherlands, 2015.

[41] T. M. Hooton, S. F. Bradley, D. D. Cardenas et al., “Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the infectious diseases society of America,” Clinical Infectious Diseases, vol. 50, no. 5, pp. 625–663, 2010.

[42] L. L. Goetz, D. D. Cardenas, M. Kennelly et al., “International spinal cord injury urinary tract infection basic data set,” Spinal Cord, vol. 51, no. 9, pp. 700–704, 2013.

[43] A. W. Stamm, S. A. Adelstein, A. Chen, A. Lucioni, K. C. Kobashi, and U. J. Lee, “Inconsistency in the definition of urinary tract infection after intravesical botulinum toxin A injection: a systematic review,” Journal of Urology, vol. 200, no. 4, pp. 809–814, 2018.

[44] NIDRR, “The prevention and management of urinary tract infections among people with spinal cord injuries,” Journal of the American Paraplegia Society, vol. 15, no. 3, pp. 194–207, 1992.

[45] A. Bakke, A. Digranes, and P. A. Hoiseth, “Physical predictors of infection in patients treated with clean intermittent catheterization: a prospective 7-year study,” BJU International, vol. 79, no. 1, pp. 85–90, 1997.

[46] R. Chaudhry, Z. R. Balsara, R. J. Madden-Fuentes et al., “Risk factors associated with recurrent urinary tract infection in neurogenic bladders managed by clean intermittent catheterization,” Urology, vol. 102, pp. 213–218, 2017.

[47] J. Krebs, P. Bartel, and J. Pannek, “Residual urine volumes after intermittent catheterization in men with spinal cord injury,” Spinal Cord, vol. 51, no. 10, pp. 776–779, 2013.

[48] J.-J. Wyndaele, A. Brauner, S. E. Geerlings, K. Bela, T. Peter, and T. E. Bjerkland-Johanson, “Clean intermittent catheterization and urinary tract infection: review and guide for future research,” BJU International, vol. 110, no. 11c, pp. E910–E917, 2012.

[49] L. M. Massa, J. M. Hoffman, and D. D. Cardenas, “Validity, accuracy, and predictive value of urinary tract infection signs and symptoms in individuals with spinal cord injury on intermittent catheterization,” Journal of Spinal Cord Medicine, vol. 32, no. 5, pp. 568–573, 2009.

[50] J. Okamoto, J. Prieto, M. Avery et al., “Intermittent catheter users’ symptom identification, description and management of urinary tract infection: a qualitative study,” BMJ Open, vol. 7, no. 9, article e016453, 2017.

[51] J. Pannek, “Treatment of urinary tract infection in persons with spinal cord injury: guidelines, evidence, and clinical practice,” Journal of Spinal Cord Medicine, vol. 34, no. 1, pp. 11–15, 2011.

[52] C. Konstantinidis and A. Karafotias, “Urinary tract infections in neuro-patients,” in Microbiology of Urinary Tract Infections-Microbial Agents and Predisposing Factors, P. Behzadi, Ed., IntechOpen Open Access Publisher, London, UK, 2018, ISBN 978-1-78984-956-1.

[53] N. Seki, K. Masuda, N. Kinukawa, K. Senoh, and S. Naito, “Risk factors for febrile urinary tract infection in children with myelodysplasia treated by clean intermittent catheterization,” International Journal of Urology, vol. 11, no. 9, pp. 973–977, 2004.

[54] J. Lapides, A. C. Diokno, S. J. Silber, and B. S. Lowe, “Clean, intermittent self-catheterization in the treatment of urinary tract disease,” Journal of Urology, vol. 107, no. 3, pp. 458–461, 1972.

[55] J. Lapides, “Mechanisms of urinary tract infection,” Urology, vol. 14, no. 3, pp. 217–225, 1979.

[56] H. Prüss, A. Tedeschi, A. Thiriot et al., “Spinal cord injury-induced immunodeficiency is mediated by a sympathetic-neuroendocrine adrenal reflex,” Nature Neuroscience, vol. 20, no. 11, pp. 1549–1559, 2017.

[57] D. J. Allison and D. S. Ditor, “Immune dysfunction and chronic inflammation following spinal cord injury,” Spinal Cord, vol. 53, no. 1, pp. 14–18, 2015.

[58] A. P. Malykhina, J.-J. Wyndaele, K.-E. Andersson, S. De Wachter, and R. R. Dmochowski, “Do the urinary bladder and large bowel interact, in sickness or in health?: ICSI-RS 2011,” Neurourology and Urodynamics, vol. 31, no. 3, pp. 352–358, 2012.

[59] P. Christensen, G. Bazzocchi, M. Coggrave et al., “A randomized, controlled trial of transanal irrigation versus conservative bowel management in spinal cord-injured patients,” Gastroenterology, vol. 131, no. 3, pp. 738–747, 2006.

[60] M. Spinelli, L. Rizzato, J. Renard, and L. Frediana, “A simple morpho-functional evaluation leads to a high transanal irrigation success rate in neurogenic bowel management,” Pelviperineology, vol. 34, no. 4, pp. 124–128, 2016.

[61] S. A. Whiteside, H. Razvi, S. Dave, G. Reid, and J. P. Burton, “The microbiome of the urinary tract—a role beyond infection,” Nature Reviews Urology, vol. 12, no. 2, pp. 81–90, 2015.
[62] M. A. Averbeck and H. Madersbacher, “Follow-up of the neuro-urolological patient: a systematic review,” BJU International, vol. 115, no. 6, pp. 39–46, 2015.

[63] J. E. Patterson and V. T. Andriole, “Bacterial urinary tract infections in diabetes,” Infectious Disease Clinics of North America, vol. 11, no. 3, pp. 735–750, 1997.

[64] O. Nitzan, M. Elias, B. Chazan, and W. Saliba, “Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management,” Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. 8, pp. 129–136, 2015.

[65] J. J. Cragg, V. K. Noonan, M. Dvorak, A. Krassioukov, G. B. J. Mancini, and J. F. Borissor, “Spinal cord injury and type 2 diabetes: results from a population health survey,” Neurology, vol. 81, no. 21, pp. 1864–1868, 2013.

[66] X. Sun, Z. B. Jones, X. M. Chen, L. Zhou, K. F. So, and Y. Ren, “Multiple organ dysfunction and systemic inflammation after spinal cord injury: a complex relationship,” Journal of Neuroinflammation, vol. 13, no. 1, p. 260, 2016.

[67] R. Reid, A. W. Bruce, R. L. Cook, and M. Llano, “Effect on urogenital flora of antibiotic therapy for urinary tract infection,” Scandinavian Journal of Infectious Diseases, vol. 22, no. 1, pp. 43–47, 1990.

[68] F. Sundén, L. Häkansson, E. Ljunggren, and B. Wullt, “Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying,” Journal of Urology, vol. 184, no. 1, pp. 179–185, 2010.

[69] R. O. Darouiche, B. G. Green, W. H. Donovan et al., “Multicenter randomized controlled trial of bacterial interference for prevention of urinary tract infection in patients with neurogenic bladder,” Urology, vol. 78, no. 2, pp. 341–346, 2011.

[70] I. Soljanik, “Efficacy and safety of botulinum toxin A intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic review,” Drugs, vol. 73, no. 10, pp. 1055–1066, 2013.

[71] S. Mouttalib, S. Khan, E. Castel-Lacanal et al., “Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment,” BJU International, vol. 106, no. 11, pp. 1677–1680, 2010.

[72] A. P. Cameron, L. Campeau, B. M. Brucker et al., “Best practice policy statement on urodynamic antibiotic prophylaxis in the non-index patient,” Neurourology and Urodynamics, vol. 36, no. 4, pp. 915–926, 2017.

[73] S.-I. Hwang, B.-S. Lee, Z.-A. Han, H.-J. Lee, S.-H. Han, and M.-O. Kim, “Factors related to the occurrence of urinary tract infection following a urodynamic study in patients with spinal cord injury,” Annals of Rehabilitation Medicine, vol. 40, no. 4, pp. 718–724, 2016.

[74] R. Miano, S. Germani, and G. VespaPian, “Stones and urinary tract infections,” Urologia Internationalis, vol. 79, no. 1, pp. 32–36, 2007.

[75] B. Welk, A. Fuller, H. Razvi, and J. Denstedt, “Renal stone disease in spinal-cord-injured patients,” Journal of Endourology, vol. 26, no. 8, pp. 954–959, 2012.

[76] M. Joshi and N. Mittal, “Bladder calculi formed over a hair nusus in spinal injury cases,” Journal of Spinal Cord Medicine, vol. 37, no. 3, pp. 346–348, 2014.

[77] J. L. Merritt, “Residual urine volume: correlate of urinary tract infection in patients with spinal cord injury,” Archives of Physical Medicine and Rehabilitation, vol. 62, no. 11, pp. 558–561, 1981.

[78] A. E. Jensen, N. Hjeltnes, J. Berstad et al., “Residual urine following intermittent catheterisation in patients with spinal cord injuries,” Spinal Cord, vol. 33, no. 12, pp. 693–696, 1995.

[79] J. K. Aronson, “Compliance, concordance, adherence,” British Journal of Clinical Pharmacology, vol. 63, no. 4, pp. 383–384, 2007.

[80] J. H. Seth, C. Haslam, and J. N. Panicker, “Ensuring patient adherence to clean intermittent self-catheterization,” Patient Preference and Adherence, vol. 8, pp. 191–198, 2014.

[81] S. I. Afas, O. U. Yemisci, S. N. S. Cosar, and N. Cetin, “Compliance with clean intermittent catheterization in spinal cord injury patients: a long-term follow-up study,” Spinal Cord, vol. 51, no. 8, pp. 645–649, 2013.

[82] S. Vahr, H. Cobussen-Boekhorst, J. Eikenboom et al., “Evidence-based Guidelines for best practice in urological health care,” in Catheterisation: Urethral Intermittent in Adults; Dilatation, Urethral Intermittent in Adults, European Association of Urology Nurses (EAUN), Arnhem, Netherlands, 2013.

[83] Y. Lotan, M. Daudon, F. Bruyère et al., “Impact of fluid intake in the prevention of urinary system diseases,” Current Opinion in Nephrology and Hypertension, vol. 22, no. 1, pp. S1–S10, 2013.

[84] S. Kilinci, M. Akman, F. Levendoglu, and R. Özker, “Diurnal variation of antiuretic hormone and urinary output in spinal cord injury,” Spinal Cord, vol. 37, no. 5, pp. 332–335, 1999.

[85] T. M. Hooton, M. Vecchio, A. Iroz et al., “Effect of increased daily water intake in premenopausal women with recurrent urinary tract infections,” JAMA Internal Medicine, vol. 178, no. 11, pp. 1509–1515, 2018.

[86] J.-J. Wyndaele and D. Maes, “Clean intermittent self-catheterization: a 12-year followup,” Journal of Urology, vol. 143, no. 5, pp. 906–908, 1990.

[87] A.-S. Goessaert, S. Antoons, M. Van Den Driessche, A. Tourchi, R. Pieters, and K. Everaert, “No-touch intermittent catheterization: caregiver point of view on sterility errors, duration, comfort and costs,” Journal of Advanced Nursing, vol. 69, no. 9, pp. 2000–2007, 2013.

[88] Semmelweis, http://history-of-handwashing.leadr.msu.edu/aftermath-of-the-germ-theory/.

[89] Koch, http://history-of-handwashing.leadr.msu.edu/aftermath-of-the-germ-theory/.

[90] P. Tenke, B. Kovacs, T. E. Bjerklund Johansen et al., “European and Asian guidelines on management and prevention of catheter-associated urinary tract infections,” International Journal of Antimicrobial Agents, vol. 31, no. 1, pp. 68–78, 2008.

[91] J. K. Aronson, “Compliance, concordance, adherence,” British Journal of Clinical Pharmacology, vol. 63, no. 4, pp. 383–384, 2007.

[92] S. Compton, L. Trease, C. Cunningham, and D. Hughes, “Australian Institute of Sport and the Australian Paralympic Committee position statement: urinary tract infection in spinal cord injured athletes,” British Journal of Sports Medicine, vol. 49, no. 19, pp. 1236–1240, 2015.

[93] M. Forchheimer, M. A. Meade, D. Tate, A. P. Cameron, G. Rodriguez, and L. DiPonio, “Self-report of behaviors to manage neurogenic bowel and bladder by individuals with chronic spinal cord injury: frequency and associated outcomes,” Topics in Spinal Cord Injury Rehabilitation, vol. 22, no. 2, pp. 85–98, 2016.
M. J. Semins, A. D. Shore, M. A. Makary, J. Weiner, and B. R. Matlaga, "The impact of obesity on urinary tract infection risk," *Urology*, vol. 79, no. 2, pp. 266–269, 2012.

W. Saliba, O. Barnett-Griness, and G. Rennert, "The association between obesity and urinary tract infection," *European Journal of Internal Medicine*, vol. 24, no. 2, pp. 127–131, 2013.

F. Faleiros, C. de Oliveira Käppler, T. Rosa, and F. R. E. Gimenes, "Intermittent catheterization and urinary tract infection: a comparative study between Germany and Brazil," *Journal of Wound, Ostomy and Continence Nursing*, vol. 45, no. 6, pp. 521–526, 2018.

R. Mays, A. McIntyre, S. Mehta, D. Hill, D. Wolfe, and R. Teasell, "A review of educational programs to reduce UTIs among individuals with SCI," *Rehabilitation Nursing*, vol. 39, no. 5, pp. 240–249, 2014.

M. Przydacz, P. Denys, and J. Corcos, "What do we know about neurogenic bladder prevalence and management in developing countries and emerging regions of the world?", *Annals of Physical and Rehabilitation Medicine*, vol. 60, no. 5, pp. 341–346, 2017.

C. J. Bennett, M. N. Young, S. S. Razi, R. Adkins, F. Diaz, and A. McCrory, "The effect of urethral introducer tip catheters on the incidence of urinary tract infection outcomes in spinal cord injured patients," *Journal of Urology*, vol. 36, no. 10, pp. 1613–1619, 2018.

R. Charbonneau-Smith, "No-touch catheterization and infection rates in a select spinal cord injured population," *Rehabilitation Nursing*, vol. 18, no. 5, pp. 296–299, 1993.

P. Denys, VaPro Study Group in France, J. G. Prévinair et al., "Intermittent self-catheterization habits and opinion on aseptic VaPro catheter in French neurogenic bladder population," *Spinal Cord*, vol. 50, no. 11, pp. 853–858, 2012.

J. Stensballe, D. Looms, P. N. Nielsen, and M. Tyve, "Hydrophilic-coated catheters for intermittent catheterisation reduce urethral micro trauma: a prospective, randomised, participant-blinded, crossover study of three different types of catheters," *European Urology*, vol. 48, no. 6, pp. 978–983, 2005.

S. Muchtar, "The importance of a lubricant in transurethral interventions," *Urologe B*, vol. 31, pp. 153–155, 1991.

J. Lundgren, O. Bengtsson, A. Israelsson, A.-C. Jönsson, A.-S. Lindh, and J. Utas, "The importance of osmolality for intermittent catheterization of the urethra," *Spinal Cord*, vol. 38, no. 1, pp. 45–50, 2000.

S. Vaidyanathan, B. M. Soni, S. Dundas, and K. R. Krishnan, "Urethral cytology in spinal cord injury patients performing intermittent catheterisation," *Spinal Cord*, vol. 32, no. 7, pp. 493–500, 1994.

J. Wyndaele, "Intermittent catheterization: which is the optimal technique?", *Spinal Cord*, vol. 40, no. 9, pp. 432–437, 2002.

P. A. Willette and S. Coffield, "Current trends in the management of difficult urinary catheterizations," *Western Journal of Emergency Medicine*, vol. 13, no. 6, pp. 427–478, 2012.

L. Hadfield-Law, "Male catheterization," *Accident and Emergency Nursing*, vol. 9, no. 4, pp. 257–263, 2001.

I. Kurze, V. Geng, and R. Bothig, "S2k-Leitlinie der Deutschen Gesellschaft für Urologie," *Der Urologe*, vol. 54, no. 3, pp. 385–393, 2015.

J. Prieto, C. L. Murphy, K. N. Moore, and M. Fader, "Intermittent catheterisation for long-term bladder management," *Cochrane Database of Systematic Reviews*, no. 9, p. CD006008, 2014.

K. Christison, M. Walter, J.-J. J. M. Wyndaele et al., "Intermittent catheterization: the devil is in the details," *Journal of Neurotrauma*, vol. 35, no. 7, pp. 985–989, 2018.

C. Rognoni and R. Tarricone, "Intermittent catheterisation with hydrophilic and non-hydrophilic urinary catheters: systematic literature review and meta-analyses," *BMC Urology*, vol. 17, no. 1, p. 4, 2017.